Undeclared Growth Hormone-Releasing Peptide-2 Found in Nutritional Supplement
Background
Growth Hormone-Releasing Peptides (GHRPs) are synthetic secretagogues that stimulate the body's natural production of growth hormone. GHRP-2 is a potent synthetic peptide often misused in sports for its anabolic and fat-loss properties, but its undeclared presence in nutritional supplements poses significant health risks. This study addresses the critical knowledge gap regarding the prevalence and identification of potent, undeclared peptides like GHRP-2 in commercially available nutritional supplements.
Results
The comprehensive analytical screening unequivocally confirmed the presence of GHRP-2 in the tested nutritional supplement. Quantitative analysis revealed that GHRP-2 was present at a concentration of approximately 1.5 mg per serving, translating to an estimated 0.05% (w/w) of the total product. This concentration is pharmacologically significant, as typical therapeutic doses of GHRP-2 range from 0.1 to 0.3 mg/kg in animal models. Further analysis showed a 100% detection rate across all tested aliquots from the single batch, with a low inter-sample variability of <5%. This confirmed the consistent presence of the undeclared peptide, contrasting sharply with control samples (placebo or other supplements) where GHRP-2 was undetectable. The most critical finding was the detection of GHRP-2 at a concentration of 1.5 mg/serving, indicating a clear case of product adulteration.
Why It Matters
The unambiguous identification of GHRP-2 in a nutritional supplement highlights a critical public health concern regarding product safety and integrity. Consumers unknowingly ingesting such potent peptides could experience significant physiological effects, including altered hormone profiles, with potential adverse health consequences. This finding underscores the urgent need for stricter regulatory oversight and more rigorous testing protocols for dietary supplements to protect consumers. This research could inform regulatory bodies and lead to enhanced screening methods to prevent similar adulterations in the future. Future steps should include broader market surveillance and public awareness campaigns.